Trials / Conditions / B-cell Adult Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia

22 registered clinical trials studyying B-cell Adult Acute Lymphoblastic Leukemia.

Status	Trial	Sponsor	Phase
Terminated	Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant NCT04044560	University of British Columbia	Phase 2
Unknown	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03185494	Chinese PLA General Hospital	Phase 1 / Phase 2
Completed	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03097770	Chinese PLA General Hospital	Phase 1 / Phase 2
Withdrawn	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin L NCT02281279	Mayo Clinic	Phase 1 / Phase 2
Unknown	Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma NCT03110640	First Affiliated Hospital of Wenzhou Medical University	Phase 1
Unknown	Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma NCT02685670	The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine	Phase 1 / Phase 2
Terminated	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non NCT02168907	Wake Forest University Health Sciences	Phase 1
Completed	Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Old NCT02228772	Massachusetts General Hospital	Phase 1
Completed	S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acu NCT01925131	SWOG Cancer Research Network	Phase 1
Unknown	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 NCT01864889	Chinese PLA General Hospital	N/A
Unknown	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory t NCT01735604	Chinese PLA General Hospital	Phase 1 / Phase 2
Withdrawn	Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Posit NCT01670084	Mayo Clinic	Phase 2
Completed	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015	City of Hope Medical Center	Phase 1
Completed	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998	National Cancer Institute (NCI)	Phase 2
Completed	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy NCT01029366	University of Pennsylvania	Phase 1
Completed	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333	Mayo Clinic	Phase 1 / Phase 2
Completed	Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia NCT00873093	National Cancer Institute (NCI)	Phase 2
Completed	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refracto NCT00867529	Fred Hutchinson Cancer Center	Phase 2
Completed	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586	Case Comprehensive Cancer Center	Phase 2
Completed	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia NCT00061945	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer NCT00010192	National Cancer Institute (NCI)	Phase 1